Prescribing information

 

Prescribing information

Welcome to the Entresto on-demand webinars page. Below you can access recordings from educational webinars that were hosted by experts in the field of heart failure and were organised by Novartis.

You will be required to register to watch the videos.

 

Screengrab of video detailing: Five years of experience with Entresto (sacubitril/valsartan): looking back and moving forward – virtual symposium

Five years of experience with Entresto (sacubitril/valsartan): looking back and moving forward – virtual symposium

A recording from the Novartis symposium at the British Society for Heart Failure’s 23rd annual autumn meeting, which took place virtually.

Prominent cardiologists Dr Patricia Campbell and Professor Mark Petrie exchange their experiences on using Entresto in the field of chronic heart failure.
 

Watch

early-initiation-entresto-screenshot

Early initiation of Entresto® (sacubitril/valsartan): alter the cycle of readmission in patients with heart failure

Watch Dr Aaron Wong and Professor Jawad Khan present how early initiation of Entresto can alter the cycle of readmission in chronic HFrEF patients, looking at local data supporting this.
 

Watch

 

Indication: Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.1

HFrEF, heart failure with reduced ejection fraction.

Reference

  1. Entresto Summary of Product Characteristics, 2020.
Rate this content: 
No votes yet
UK | June 2021 | 126431
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]